Abstract: A device for providing an energetic field to promote the body's self-healing process comprises electronics immersed in a dialectric oil in a first enclosure which accelerate and spin an energetic current within a gas-filed glass tube. The tube protrudes through a small opening into a second large metal (e.g. copper)-lined patient enclosure, such that the energy emitted from the tube is directed toward a circular concave baffle covered in a densely woven fabric. A plastic sheet optionally protects the patient from arcing with the baffle. Seating/support is provided to properly position the patient; as well as seating for the practitioner/therapist who both positions the patient, and provides mental and emotional guidance, to optimize patient receptivity to treatment.

Abstract: In one example in accordance with the present disclosure a method of normalizing cytokine levels in a blood stream of a subject is described. According to the method, an array of electromagnetic emitters is positioned proximal to the subject. An electromagnetic wave generator generates electromagnetic fields having a predetermined frequency. Cytokine levels are normalized in the blood stream of the subject by applying the electromagnetic fields to the subject through the electromagnetic emitters.

Abstract: A method for treating movement disorders is provided. The method includes the following operations. A central nervous signal of a patient with movement disorders is recorded. A first stimulation is delivered from a stimulator to the patient when an oscillation episode in a range of from about 3 Hz to about 20 Hz is observed in the central nervous signal. The first stimulation is adapted according to a measurable feature of the oscillation episode. The system for treating movement disorders is also provided.

Abstract: The present invention provides devices and methods for modulating spreading depression in the brain.

Abstract: A blood pump system is implantable in a patient for ventricular support. A pumping chamber has an inlet for receiving blood from a ventricle of the patient. An impeller is received in the pumping chamber. A motor is coupled to the impeller for driving rotation of the impeller. A motor controller is provided for tracking systolic and diastolic phases of a cardiac cycle of the patient and supplying a variable voltage signal to the motor in a variable speed mode to produce a variable impeller speed linked to the cardiac cycle. The impeller speed comprises a ramping up to an elevated speed during the diastolic phase in order to reduce a load on the ventricle at the beginning of the systolic phase.

Abstract: The technology provides a system and method for simulating and detecting bio signals such as brain bio-signals. Optical fibers provide modulated signals received from an optical signal modulator. The modulated signals are received by a set of emission elements disposed within the phantom body, which output corresponding electrical signals. The electrical signals are detected by a set of sensors and evaluated by a receiver device, such as for an electroencephalograph (EEG), electrocardiogram (ECG), electromyogram (EMG) or magnetoencephalography (MEG) diagnostic system. A controller manages the modulation of light signals so that specific electrical signals can be generated as desired. Because tens, hundreds or thousands of emission elements may be arranged in the phantom body, the controller can manage operation of the optical signal modulator so that the precise physical location of each emission element can be mapped quickly and efficiently.

Abstract: Devices and methods can be used for artificial cardiac pacing and/or resynchronization. For example, this document provides improved electrodes for stimulating and sensing electrical activity of the heart, and provides pacing and resynchronization systems incorporating such electrodes. While the devices and methods provided herein are described primarily in the context of pacing, it should be understood that resynchronization can additionally or alternatively be performed in an analogous manner, and that the scope of this disclosure includes such subject matter.

Abstract: Embodiments herein relate to a medical device for treating a cancerous tumor, the medical device having a first lead including a first wire and second wire; a second lead can include a third wire and fourth wire; and a first electrode in electrical communication with the first wire, a second electrode in electrical communication with the second wire, a third electrode in electrical communication with the third wire, and a fourth electrode in electrical communication with the fourth wire. The first and third electrodes form a supply electrode pair configured to deliver one or more electric fields to the cancerous tumor. The second and fourth electrodes form a sensing electrode pair configured to measure an impedance of the cancerous tumor independent of an impedance of the first electrode, the first wire, the third electrode, the third wire, and components in electrical communication therewith. Other embodiments are also included herein.

Abstract: Described is a method of treating a subject diagnosed with cancer, breast cancer, bone cancer, lung cancer, osteoporosis, multiple myeloma, and a combination of any thereof by applying a bioelectric signal or signals that upregulate the expression of Osteoprotegerin (“OPG”) and thus beneficially effect the subject's OPG/RANKL/RANK pathway.

Abstract: A method of replacing a neurostimulator device. The method including explanting a previously implanted neurostimulator device from a site; operably coupling a replacement neurostimulator device to a previously implanted stimulation lead; and implanting a replacement neurostimulator device within the site, the replacement neurostimulator device having a volume of about ten cc's or less, and the previously implanted neurostimulator device having a volume of greater than about ten cc's.

Abstract: A sensor interface system for providing a connection between at least one sensor and a maternal-fetal monitor, wherein the interface system converts electrical muscle activity captured by the sensor(s) into uterine activity data signals for use by the maternal-fetal monitor. The sensor interface system of the invention preferably includes a conversion means for converting the signals from the sensor(s) into signals similar to those produced by a tocodynamometer.

Abstract: Systems and methods are provided for analyzing electrocardiogram (ECG) data of a patient using a substantial amount of ECG data. The systems receive ECG data from a sensing device positioned on a patient such as one or more ECG leads. The system may include an application that communicates with an ECG platform running on a server(s) that processes and analyzes the ECG data, e.g., using neural networks for delineation of the cardiac signal and classification of various abnormalities, conditions and/or descriptors. The processed ECG data is communicated from the server(s) for display in a user-friendly and interactive manner with enhanced accuracy.

Abstract: A first optical subsystem includes a window with a refractive index nw and an exit lens having a refractive index nx. The exit lens is configured to couple to the window to define a first optical axis extending through the window and the exit lens. A second optical subsystem is configured to output a light beam. The light beam is directed to be incident at a convex surface of the exit lens along a second optical axis at an angle ? that is offset from the first optical axis. The window is configured to detachably couple to the cornea of the eye such that the first optical axis is generally aligned with a direction of view of the eye. The respective refractive indices nw and nx are configured to direct the light beam incident at the convex surface of the exit lens through the cornea of the eye toward the irido-corneal angle.

Abstract: A device intended to be implanted in a human or animal body, in order to produce hydrogen in situ from molecules present in the body medium in which the device is implanted, this device having an anode and a cathode, which are each electrically connected to a pole of an electrical energy source, and having a semi-permeable material separating the electrodes from the body medium, in which device, when the connection to the electrical energy source is effective in situ, in the presence of body fluid, a closed electrical circuit is formed, with production of hydrogen at the cathode, the semi-permeable material having a cutoff threshold of between 50 and 500 Da.

Abstract: Stimulation using EA of LI-4, LI-11, GV-14 and GV-20 in humans, horses, and rodents results in mobilization of MSCs into systemic circulation. Methods are provided for increasing mesenchymal stem cells in the circulating blood of a mammal by contacting acupuncture points LI-4, LI-11, GV-14, and GV-20 of the mammal with a therapeutically effective amount of EA stimulation to mobilize MSCs into the circulating blood of the mammal. Methods for treating damaged tissue, specifically damaged tendons are also provided. Isolated mesenchymal stem cells made according to these methods, methods of isolated them, and stem cell banks that store them are also provided.

Abstract: An example of an apparatus for percutaneously delivering neurostimulation energy to a patient and sensing from the patient using a test device placed externally to the patient is provided. The apparatus may include a stimulation lead, a sensing reference electrode, a sensing wire, and a connection system. The stimulation lead may be configured to be percutaneously introduced into the patient to place the one or more electrodes in the patient. The sensing reference electrode may be configured to be placed in the patient. The sensing wire may be connected to the sensing reference electrode and configured to be percutaneously introduced into the patient to place the sensing reference electrode in the patient. The connection system may be configured to mate the lead connector and the wire connector and to provide electrical connections between the lead connector and the test device and between the wire connector and the test device.

Abstract: The present disclosure provides a neuromodulation method for treating neurodegenerative disease. The neuromodulation method comprises attaching a first active electrode to a patient's leg in the back of the knee area in an expected location of a peroneal nerve of the first leg and attaching a grounding electrode to the patient's body. Generating electrical pulses by a pulse generator connected to the first active electrode and the grounding electrode. Stimulating by the first active electrodes the peroneal nerve of the first leg and controlling via a control unit a flow of the generated pulses to the first electrode.

Abstract: A catheter pump is disclosed. The catheter pump can include an impeller and a catheter body having a lumen therethrough. The catheter pump can also include a drive shaft disposed inside the catheter body. A motor assembly can include a chamber. The motor assembly can include a rotor disposed in the at least a portion of the chamber, the rotor mechanically coupled with a proximal portion of the drive shaft such that rotation of the rotor causes the drive shaft to rotate. The motor assembly can also comprise a stator assembly disposed about the rotor. The motor assembly can also include a heat exchanger disposed about the stator assembly, the heat exchanger may be configured to direct heat radially outward away from the stator assembly, the rotor, and the chamber.

Abstract: An implantable medical system may provide atrioventricular synchronous pacing using the ventricular septal wall. The system may include a ventricular electrode coupled to an intracardiac housing or a first medical lead implantable in the ventricular septal wall of the patient's heart to deliver cardiac therapy to or sense electrical activity of the left ventricle of the patient's heart and a right atrial electrode coupled to a leadlet or second medical lead to deliver cardiac therapy to or sense electrical activity of the right atrium of the patient's heart. A right ventricular electrode may be coupled to the intracardiac housing or the first medical lead and implantable in the ventricular septal wall of the patient's heart to deliver cardiac therapy to or sense electrical activity of the right ventricle of the patient's heart.

Abstract: A hermetically sealed feedthrough assembly for an active implantable medical device having an oxide-resistant electrical attachment for connection to an EMI filter, an EMI filter circuit board, an AIMD circuit board, or AIMD electronics. The oxide-resistant electrical attachment, including an oxide-resistant sputter layer 165 is disposed on the device side surface of the hermetic seal ferrule over which an ECA stripe is provided. The ECA stripe may comprise one of a thermal-setting electrically conductive adhesive, an electrically conductive polymer, an electrically conductive epoxy, an electrically conductive silicone, an electrically conductive polyimides, or an electrically conductive polyimide, such as those manufactured by Ablestick Corporation. The oxide-free electrical attachment between the ECA stripe and the filter or AIMD circuits may comprise one of gold, platinum, palladium, silver, iridium, rhenium, rhodium, tantalum, tungsten, niobium, zirconium, vanadium, and combinations or alloys thereof.